Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Canopy Growth CorporationNASDAQ: CGC
Accounts Receivables · Q4 FY2025 · quarter ended Mar 2026
Accounts receivables turns positive
Q4 FY2025 accounts receivables was CA$6.08M, compared with -CA$1.32M a year earlier. Trailing-twelve-month accounts receivables was CA$23.54M. Over 3 fiscal years it compounded at +60.2% a year.
Context
- Accounts receivables amounted to 5.3% of revenue in FY2025, up 3.6 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near CA$6.08M or moves back toward the trailing-twelve-month quarterly average of CA$5.88M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
CAD · from the cash flow
- Latest · FY2025
- 25.69M CAD
- Year-over-year change
- +672.7%
- 4-year CAGR
- +12.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 25.69M | +672.7% |
| FY2024 | 2025-03-31 | (4.49M) | -19.6% |
| FY2023 | 2024-03-31 | (3.75M) | -160.1% |
| FY2022 | 2023-03-31 | 6.24M | -61.4% |
| FY2021 | 2022-03-31 | 16.15M | — |
Accounts Receivables vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +624.8% is the 2nd highest of 7, against a peer median of -80.0%.
- Accounts receivables amounts to 7.5% of revenue for CGC, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.07M USD | -304.9% | +63.8% | 18.3% | |
| LTM Mar 2026 | CA$23.54M CAD | +624.8% | +60.2% | 7.5% | |
| LTM Mar 2026 | $8.6M USD | — | -28.3% | 6.4% | |
| LTM Mar 2026 | CA$8.17M CAD | -225.0% | — | 2.6% | |
| LTM Mar 2026 | $6.81M USD | +5438.2% | +253.5% | 81.4% | |
| LTM Mar 2026 | $4.29M USD | -67.1% | — | 1.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $348K USD | -3.6% | — | 3.4% |
| LTM Mar 2026 | $86K USD | -93.0% | — | 0.2% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding CGC) | — | -80.0% | +63.8% | 3.0% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (258.91M) | (3.08B) | (483.68M) | (604.14M) | (366.64M) |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| Deferred Income Tax | (8.95M) | (5.73M) | 12.33M | 7.14M | 0 |
| Stock-Based Compensation | 46.69M | 25.32M | 14.18M | (4.21M) | 5.95M |
| Change in Working Capital | 205M | 58.97M | 3.97M | (31.97M) | 20.68M |
| Accounts Receivables | 16.15M | 6.24M | (3.75M) | (4.49M) | 25.69M |
| Inventory | 204.22M | 68.44M | 1.03M | (17.72M) | 3.71M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (15.37M) | (15.71M) | 6.68M | (9.77M) | (8.72M) |
| Other Non-Cash Items | (640.58M) | 2.36B | 118.08M | 424.3M | 200.17M |
| Operating Cash Flow | (545.81M) | (557.55M) | (281.95M) | (165.75M) | (88.98M) |
| Capital Expenditures | (48.11M) | (10.45M) | (4M) | (11.28M) | (7.44M) |
| Acquisitions (Net) | 103.2M | 14.93M | (955K) | (6.97M) | 0 |
| Purchases of Investments | (379.41M) | (67.15M) | (347K) | (95.34M) | 0 |
| Sales of Investments | 546.01M | 502.59M | 78.55M | 16.43M | 26.5M |
| Other Investing Activities | (2.3M) | (7.88M) | 167.79M | 48.9M | (48.83M) |
| Investing Cash Flow | 230.82M | 433.38M | 241.59M | (47.79M) | (29.77M) |
| Debt Repayment | (50.76M) | 16.98M | (509.78M) | (220.78M) | (24.62M) |
| Common Stock Issued | 2.7M | 1.05M | 81.06M | 385.39M | 374.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.53M | (37.72M) | (36.34M) | (15.96M) | 114.02M |
| Financing Cash Flow | (45.53M) | (19.69M) | (465.06M) | 148.66M | 463.57M |
| Effect of Forex Changes | (18.12M) | 44.86M | (1.29M) | 8.39M | 5.05M |
| Net Change in Cash | (378.65M) | (99M) | (506.71M) | (56.49M) | 349.86M |
| Free Cash Flow | (593.92M) | (568M) | (285.95M) | (177.03M) | (96.42M) |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.